OncoMatch/Clinical Trials/NCT06200168
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
Is NCT06200168 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Electroacupuncture and Standard antiemetic treatment for electroacupuncture.
Treatment: Electroacupuncture · Standard antiemetic treatment · Sham electroacupuncture · Standard antiemetic treatment — This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: early-stage patients must not have undergone prior chemotherapy; advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months
Patients already submitted to chemotherapy
Cannot have received: acupuncture
Received acupuncture treatments for any conditions less than 4 weeks before HEC
Cannot have received: radiation therapy
Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1
Lab requirements
Blood counts
Adequate bone marrow function; significantly abnormal platelets, coagulation indexes, absolute neutrophils excluded
Kidney function
Adequate kidney function; significantly abnormal creatinine excluded
Liver function
Adequate liver function; significantly abnormal AST, ALT, bilirubin excluded
Adequate bone marrow, kidney, and liver function; Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify